Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex F Herrera

Showing results (1-10 of 174) with videos related to

Pageof 18
Sort By:
Clinical Advances in Hematology & Oncology : H&O|November 16, 2019
Highlights in Lymphoma From the 60th American Society of Hematology Annual Meeting: CommentaryAlex F Herrera
Clinical Advances in Hematology & Oncology : H&O|March 28, 2025
Is there a new standard-of-care therapy for advanced Hodgkin lymphoma?Alex F Herrera
Journal of Oncology Practice|March 11, 2016
Double-Hit Lymphoma: Practicing in a Data-Limited SettingAlex F Herrera
Hematology/Oncology Clinics of North America|June 24, 2019
Noncellular Immune Therapies for Non-Hodgkin LymphomaAlex F Herrera
Hematology. American Society of Hematology. Education Program|December 4, 2018
Where does PD-1 blockade fit in HL therapy?Alex F Herrera
Clinical Advances in Hematology & Oncology : H&O|March 22, 2021
Highlights in Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting: CommentaryAlex F Herrera
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2017
Minimal Residual Disease Assessment in Lymphoma: Methods and ApplicationsAlex F Herrera, Philippe Armand
Blood Advances|December 4, 2024
New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trialsChijioke Nze, Alex F Herrera
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 15, 2021
Advances in Immunotherapy for Diffuse Large B Cell LymphomaGeoffrey Shouse, Alex F Herrera
Blood|April 23, 2021
How I incorporate novel agents into the treatment of classical Hodgkin lymphomaNarendranath Epperla, Alex F Herrera
Pageof 18

Showing results (1-10 of 174) with videos related to

Sort By:
Pageof 18
Clinical Advances in Hematology & Oncology : H&O|November 16, 2019
Highlights in Lymphoma From the 60th American Society of Hematology Annual Meeting: CommentaryAlex F Herrera
Clinical Advances in Hematology & Oncology : H&O|March 28, 2025
Is there a new standard-of-care therapy for advanced Hodgkin lymphoma?Alex F Herrera
Journal of Oncology Practice|March 11, 2016
Double-Hit Lymphoma: Practicing in a Data-Limited SettingAlex F Herrera
Hematology/Oncology Clinics of North America|June 24, 2019
Noncellular Immune Therapies for Non-Hodgkin LymphomaAlex F Herrera
Hematology. American Society of Hematology. Education Program|December 4, 2018
Where does PD-1 blockade fit in HL therapy?Alex F Herrera
Clinical Advances in Hematology & Oncology : H&O|March 22, 2021
Highlights in Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting: CommentaryAlex F Herrera
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2017
Minimal Residual Disease Assessment in Lymphoma: Methods and ApplicationsAlex F Herrera, Philippe Armand
Blood Advances|December 4, 2024
New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trialsChijioke Nze, Alex F Herrera
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 15, 2021
Advances in Immunotherapy for Diffuse Large B Cell LymphomaGeoffrey Shouse, Alex F Herrera
Blood|April 23, 2021
How I incorporate novel agents into the treatment of classical Hodgkin lymphomaNarendranath Epperla, Alex F Herrera
Pageof 18